

- **Full Name:** Chung Ryul Oh
 - **Current Position & Affiliation:** Clinical Assistant Professor, Chung-Ang University Hospital
 - **Country:** Republic of Korea
-

• Educational Background:

- 2007.03 ~ 2013.02 M.D., Eulji University College of Medicine, Daejeon, Korea
- 2016.03 ~ 2018.02 M.S., Ulsan University College of Medicine, Seoul, Korea

• Professional Experience:

- 2013.03 ~ 2014.02 Internship, Asan Medical Center, Seoul, Korea
- 2014.03 ~ 2018.02 Residency, Internal Medicine, Asan Medical Center, Seoul, Korea
- 2021.03 ~ 2022.02 Fellowship, Medical Oncology, Asan Medical Center, Seoul, Korea
- 2022.03 ~ Present Clinical Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea

• Professional Organizations:

- Korean Medical Association
- Korean Association of Internal Medicine
- Korean Society of Medical Oncology (KSMO)
- Korean Cancer Association
- Korean Cancer Study Group

• Main Scientific Publications:

1. Epithelial-Mesenchymal Transition Phenotype and Peritumoral Immune Cell Infiltration in Advanced Biliary Tract Cancer. *Anticancer Res.* 2023 Feb;43(2):645-652. doi: 10.21873/anticancerres.16201.
2. Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02. *Clin Oncol (R Coll Radiol).* 2023 Feb;35(2):e143-e152. doi: 10.1016/j.clon.2022.10.016.
3. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. *Int J Cancer.* 2022 Jun 15;150(12):2038-2045. doi: 10.1002/ijc.33966.
4. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. *Cancer Res Treat.* 2021 Apr;53(2):291-300. doi: 10.4143/crt.2020.1233.

5. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. *Target Oncol.* 2020 Aug;15(4):485-493. doi: 10.1007/s11523-020-00731-z.
6. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. *BMC Cancer.* 2019 Apr 1;19(1):292. doi: 10.1186/s12885-019-5483-x.